Junen Sun
Fosun Pharma (China)(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Hepatocellular Carcinoma Treatment and Prognosis, Rheumatoid Arthritis Research and Therapies, Angiogenesis and VEGF in Cancer, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy(2014)151 cited
- → Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases(2017)5 cited
- → Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib(2022)4 cited
- → Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification.(2013)4 cited
- → HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo(2016)2 cited
- → Abstract 1730: A study on EGFR gene amplification and protein expression in Chinese esophagus cancer patients and antitumor effect of an EGFR inhibitor in patient-derived esophagus cancer models(2014)